Effect of Imidafenacin before Sleeping on Nocturia
Article first published online: 20 MAR 2012
© 2012 Wiley Publishing Asia Pty Ltd
LUTS: Lower Urinary Tract Symptoms
Volume 4, Issue 3, pages 130–135, September 2012
How to Cite
KADEKAWA, K., ONAGA, T., SHIMABUKURO, S., SHIMABUKURO, H., SAKUMOTO, M., ASHITOMI, K., NISHIJIMA, S. and SUGAYA, K. (2012), Effect of Imidafenacin before Sleeping on Nocturia. LUTS: Lower Urinary Tract Symptoms, 4: 130–135. doi: 10.1111/j.1757-5672.2012.00147.x
- Issue published online: 9 SEP 2012
- Article first published online: 20 MAR 2012
- Received 28 November 2011; revised 31 January 2012; accepted 15 February 2012.
- anticholinergic agent;
- overactive bladder
Objectives: Clinical efficacy, influence on quality of life (QOL), and safety of imidafenacin before sleeping were assessed in patients with overactive bladder (OAB) who suffered from nocturia.
Methods: A total of 60 OAB patients with a mean age of 74 years (45 men and 15 women) who mainly complained of nocturia were enrolled. Imidafenacin (0.1 mg) was administered once daily before sleeping for four weeks. Then the patients were divided into two groups, “a stable-dose group” with sufficient efficacy who remained on 0.1 mg of imidafenacin daily, and “a dose-escalation group” with insufficient efficacy in whom the daily dose of imidafenacin was increased to 0.2 mg before sleeping. Lower urinary tract symptoms and postvoid residual volume (PVR) were examined before treatment and after 4 and 8 weeks of imidafenacin therapy.
Results: In the stable-dose group, nighttime frequency decreased significantly from 3.4 ± 1.1 to 2.3 ± 1.1 and 2.6 ± 2.0 times after four and eight weeks, respectively. In the dose-escalation group, nighttime frequency did not change significantly (from 3.8 ± 1.5 to 3.6 ± 1.8 times) at four weeks, but decreased significantly to 2.8 ± 1.4 times at eight weeks. Daytime frequency, OAB symptom score, and IPSS-QOL index score were significantly improved in both groups at four and/or eight weeks. There was no increase of PVR and no serious adverse events.
Conclusion: Administration of imidafenacin at 0.1–0.2 mg once daily before sleeping was safe and effective for the treatment of OAB with the main symptom of nocturia.